Adams Delays New Humibid Launches, Mucinex Drives Record Overall Sales
This article was originally published in The Tan Sheet
Executive Summary
In the midst of strong growth from flagship brand Mucinex, Adams is delaying the launch of new Humibid products to train pharmacists in behind-the-counter sale of the OTC drug
You may also be interested in...
Adams May Cough Up Humibid As Product Confusion Congests Sales
Adams Respiratory Therapeutics is considering whether to stop offering its Humibid 1,200 mg guaifenesin product, which it markets voluntarily behind the counter, as it launches an over-the-counter version of the same product under the name Maximum Strength Mucinex
Adams Tackles Branding By Linking Mucinex To Mucus, Not Indications
Adams Respiratory Therapeutics competes head on with larger firms in the over-the-counter market, but on its own terms using untraditional approaches to building brand recognition, Adams President and CEO Michael Valentino says
Adams Pulls Off Trade For Mucinex Complement
Adams Respiratory Therapeutics is expanding its guaifenesin cough/cold portfolio with the addition of Cornerstone BioPharma's Humibid line